BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-39@pharmaconomics
DTSTAMP:20260707T003630Z
DTSTART;VALUE=DATE:20261028
DTEND;VALUE=DATE:20261029
SUMMARY:MRK Phase 3 — Belzutifan
DESCRIPTION:Phase 3 trial results for Belzutifan in Carcinoma\, Renal Cell are due Oct 28\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT05239728\n\nTrack it: https://pharmaconomics.com/e/39
URL:https://pharmaconomics.com/e/39
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:MRK catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR